Joseph Skowron III, a former manager at hedge fund FrontPoint Partners, admitted last year that he directed several FrontPoint healthcare funds to sell shares in biotechnology company Human Genome Sciences Inc. in 2008 based on inside information he obtained about clinical drug trials from a French doctor. The move allegedly allowed him to avoid about $30m in trading losses, federal prosecutors said.